About Cessatech
Cessatech is a pivotal-stage biotech company dedicated to rethinking medicines for children by addressing significant unmet paediatric needs, particularly in hospital and emergency settings. By repositioning well-known medicines into child-friendly formulations and delivery methods, Cessatech reduces development risk and accelerates time to market. Cessatech’s strategy is to grow the business through strong partnerships that support regulatory execution and commercial success across key markets. Cessatech is located in Hellerup, Denmark and led by a seasoned team with a proven track-record within drug development and product launches, in Europe, US and Asia.
Business model
Our strategic focus
Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a focused development plan can be applied for documenting good effect in children
From Rigshospitalet
History
Cessatech is a spinout project from Rigshospitalet, a project lead by experts within paediatric anaesthesia and pain treatment, who recognized a need for fast-acting and easy to use needle-free pain treatment for children. Children, like adults, have a right to the highest attainable standard of health, but continue to be under-represented in medication research, as well as drug development What started with co-founder Bettina Nygaard Nielsen’s PhD dissertation from 4 years of research, supervised by co-founder Steen Henneberg, has today developed into a company focusing on the improvement of paediatric care, specialized in the development of innovative pharmaceuticals in age-appropriate formulations intended for use in children.
Leadership team
Jes Trygved
Chief Executive Officer (CEO)
Malene Cording
Head of Clinical Development & Operations
Martin Juhl
Chief Scientific Officer - Head of CMC & Device Development & Operations
Louise Bak
Head of Regulatory Affairs
Sarah Margaux Toft-Jørgensen
Senior Director, Finance & Investor Relations
Board of Directors
Martin Olin (Chairman)
Board Member since 2020 - Current position: CEO BerGenBio
Rachel Curtis Gravesen
Board Member since 2022 - Current position: Board member & consultant
Flemming Steen Jensen
Board Member since 2020 - Current position: Senior Vice President, Ascendis Pharma A/S
Charlotte Videbæk, MD
Board Member since 2020 - Current position: Board member & entrepreneur
hi